Essex Woodlands Healthcare Partners

Enercon Technologies is an electronics manufacturing company that provides product development, testing, marketing, and design services.

TELA Bio is a life science company that specializes in soft tissue reconstruction. The company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair.

VitalConnect develops wearable biosensor technology designed for wireless patient monitoring. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms. The company's products are designed for inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions.

Laboratoires Majorelle was founded with the ambition to become the first pharmaceutical company with a responsible approach dedicated to the resolution of public health concerns. Their mission is to address the main public health needs,improve essential medicines access to as many people as possible. French independent pharmaceutical company, Majorelle bases its expertise in the field of sexual health, in order to offer health answers which care for men and women in France.

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.

Metabolon is a technology company, that develops analytical methods and software for biomarker discovery using metabolomics. Metabolon's expertise in data and translational science enables customers and partners to tackle some of the most complex and urgent questions in the life sciences, thereby accelerating research and improving development outcomes. The company provides scalable and customizable multiomics solutions, including metabolomics and lipidomics, to support customer needs from discovery through clinical trials and throughout the product lifecycle. The company aims to provide biochemical data and insights that broaden and hasten the impact of life sciences research, while also integrating seamlessly with other 'omics' technologies.

Cardiva Medical is a medical device company that’s focused on developing and commercializing innovative vascular closure technology designed to help the body heal itself following catheterization. The company’s products include VASCADE, a vascular closure system, and Catalyst II and Catalyst III, which are designed to aid manual compression. It was founded in 2002 and headquartered in Sunnyvale, California.

MiMedx Group developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. They processes the human placental tissue utilizing its proprietary purion process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization.

Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today.

Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

Venus Concept is a progressive-thinking company driven by their passion to create cutting-edge technologies and products. While resting on strong ethical morals, they push boundaries in order to create new standards in the medical aesthetics industry. Led by a team of experienced executives and researchers, world renowned for their achievements in the medical aesthetics industry, Venus Concept is delivering on the promise of a more effective, more pleasant, and more profitable experience.

Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today.

BioTissue is an innovative technology company that uses products derived from human amniotic and umbilical cord tissues. Its medical technology platform markets innovative amniotic and umbilical cord-based products, thereby enabling physicians to avail of enhanced regenerative healing technology in eye care, wound care, and orthopedics. Tissuetech was founded in 2001 and is headquartered in Miami, Florida.

Encore Dermatology is a privately held fully-integrated dermatology company that provides prescription therapies and medical devices to dermatologists. It provides a range of medical dermatology products, treating a number of topical disease states that enable patients to get improved skin care and treatment with ease. Encore Dermatology was established in 2015 and is headquartered in Malvern, Pennsylvania.

EyePoint Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases, primarily in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. EyePoint is also advancing its pipeline with EYP-1901, a bioerodible implant targeting wet age-related macular degeneration and related conditions, as well as YUTIQ50 for uveitis. The company utilizes its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems. EyePoint has established strategic collaborations with various organizations and engages in a commercial alliance for the promotion of its products. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was previously known as pSivida Corp.

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.

Venus Concept is a progressive-thinking company driven by their passion to create cutting-edge technologies and products. While resting on strong ethical morals, they push boundaries in order to create new standards in the medical aesthetics industry. Led by a team of experienced executives and researchers, world renowned for their achievements in the medical aesthetics industry, Venus Concept is delivering on the promise of a more effective, more pleasant, and more profitable experience.

Xenex is offering an effective approach to reducing the incidence of healthcare-associated infections. The Xenex mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital-acquired infections (HAIs). Xenex’s Pulsed Xenon Full Spectrum™ UV Disinfection Solution reduces the bacterial load often associated with an increased risk for HAIs. Since its commercial launch in June 2010, Xenex devices are now included in infection control protocols in almost three hundred hospitals throughout the U.S. Xenex was founded in 2009 and headquartered in San Antonio, Texas.

Prolacta Bioscience, Inc. (www.prolacta.com) is a life science company founded by serial entrepreneur, Elena Medo who has dedicated her career to improving quality of life for sick infants by Advancing the Science of Human MilkTM. Prolacta creates specialty formulations made exclusively from human milk for the nutritional needs of critically ill, premature infants in neonatal intensive care units. It is the first and only company to provide a human milk fortifier made from 100% human milk, Prolact+ H2MF. They operate a pharmaceutical grade processing plant and have designed and patented processes that enable them to make their one-of-a-kind life saving products. Prolacta is committed to making a meaningful difference in the lives of the most vulnerable infants through world-class research and innovative products.

Metabolon is a technology company, that develops analytical methods and software for biomarker discovery using metabolomics. Metabolon's expertise in data and translational science enables customers and partners to tackle some of the most complex and urgent questions in the life sciences, thereby accelerating research and improving development outcomes. The company provides scalable and customizable multiomics solutions, including metabolomics and lipidomics, to support customer needs from discovery through clinical trials and throughout the product lifecycle. The company aims to provide biochemical data and insights that broaden and hasten the impact of life sciences research, while also integrating seamlessly with other 'omics' technologies.

Suneva Medical is a privately held medical technology company focused on developing, manufacturing, and commercializing novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It provides novel and differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. The company’s flagship brand, Bellafill, is the only dermal filler on the market with five-year safety and efficacy data, and the only dermal filler approved for the correction of facial acne scars. The Suneva Medical product portfolio focuses on compelling, differentiated products that deliver high patient satisfaction and represent a significant business opportunity for its practice partners. The company was founded in 2015 and is headquartered in San Diego, California.

Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical identification and treatment of evaporative dry eye. Of the 100 million plus of dry eye sufferers worldwide, the leading cause (86percent) is evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye.

Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

QSpex Technologies, Inc. has developed a unique and patented method to produce high quality premium lenses right in your office. It’s simple, cost effective and, above all, the lenses and treatment options provide the high quality you demand for your patients. All lens treatments are pre-applied to the inside surface of each mold and transfer to become part of the lens during the polymerization (curing) process.

Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems.

Catalyst Biosciences is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and coagulation systems. They create novel catalytic biopharmaceutical products based on engineered human proteases.

Yantai Beacon Medical is a provider of medical gas systems and purification engineering services. Formerly known as Yantai Beacon Group Company Limited, Yantai Beacon was established in 1999 and is based in China.

Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

BreatheAmerica provides treatment facilities for patients suffering from breathing and other related allergic problems. BreatheAmerica is a company dedicated to improving how healthcare services are delivered to patients who suffer from chronic airway diseases - allergy, sinusitis, asthma, and other related diseases - with the goal of improving outcomes, reducing healthcare expenditures, and delivering an exceptional, differentiated patient experience. Joseph C. Hutts and Derril Reeves formed the company in Nashville, Tennesee in 2006.

Catalyst Biosciences is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and coagulation systems. They create novel catalytic biopharmaceutical products based on engineered human proteases.

QSpex Technologies, Inc. has developed a unique and patented method to produce high quality premium lenses right in your office. It’s simple, cost effective and, above all, the lenses and treatment options provide the high quality you demand for your patients. All lens treatments are pre-applied to the inside surface of each mold and transfer to become part of the lens during the polymerization (curing) process.

Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

IntegenX, Inc. designs, manufactures, and markets automation systems that enable reliable microsample preparation and analysis for the life sciences. It offers Apollo 100, a platform that allows the processing of DNA sequencing reactions; Apollo 200, an integrated sample preparation system for human DNA identification; microfluidics for DNA sequencing, molecular diagnostics, and human identification applications; and Apollo 324 system, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation sequencing. The company was formerly known as Microchip Biotechnologies, Inc. and changed its name to IntegenX, Inc. in March 2010. The company was incorporated in 2003 and is based in Pleasanton, California.

Biotoscana Group (GBT) is a fast growing biopharmaceutical company in Latin America. The group was established through the merger of two leading specialty pharmaceutical companies, each with over 25 years experience in their respective markets: Biotoscana, founded in 1984, and United Medical, founded in 1987, sells leading brands GBT fields highly complex genetic disorders, rare diseases, oncology, hematology and specialized treatments, and has long-standing partnerships with leading global players in the pharmaceutical field.

BreatheAmerica provides treatment facilities for patients suffering from breathing and other related allergic problems. BreatheAmerica is a company dedicated to improving how healthcare services are delivered to patients who suffer from chronic airway diseases - allergy, sinusitis, asthma, and other related diseases - with the goal of improving outcomes, reducing healthcare expenditures, and delivering an exceptional, differentiated patient experience. Joseph C. Hutts and Derril Reeves formed the company in Nashville, Tennesee in 2006.

Entellus Medical is focused on providing unique solutions to the unmet needs of the ENT (ear, nose and throat) physician, their patients, and payers through the development of innovative device technology and treatment solutions. Entellus is based in Maple Grove, MN and markets products throughout the United States. Entellus Medical works closely with leading researchers and clinicians to develop solutions that benefit patients, physicians, and payers. Entellus provides a simple, direct and effective treatment for Chronic Rhinosinusitis (CRS) that is less invasive, reduces pain and bleeding, shortens recovery time, and eliminates the need for general anesthesia. Entellus recently introduced FinESSâ„¢ Sinus Treatment, a simple and direct approach to effectively treat patients with CRS. FinESS can be performed under local anesthesia, with or without light sedation, and remodels the maxillary ostium and the ethmoid infundibulum using a micro endoscope and a small balloon catheter. Unlike sinus surgery techniques, FinESS does not require the removal of delicate bone or sinus tissue, resulting in shorter treatment time with very little pain or bleeding. Recovery time is usually one to two days with many patients resuming normal activity within a day.

Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.

Endologix develops and manufactures minimally invasive treatments for aortic disorders. Endologix's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S.

Alpha Innotech Corp. manufactures and sells analytical laboratory instruments, software, and consumables used in life science research laboratories for the study of nucleic acids, proteins, and cells worldwide. Products The company's imaging systems, sold under its trademarks AlphaDigiDoc, AlphaImager, FluorChem and red, comprise a digital camera and bench-top dark enclosure and are used to detect, archive, and analyze fluorescent, chemiluminescent and visible signals from biological samples, such as DNA, proteins and bacterial colonies. Alpha Innotech Corp. was founded in 1992.

Accumetrics is a privately-held company that develops, manufactures, and markets the VerifyNow System, a comprehensive suite of assays for the assessment of platelet function. Accumetrics, based in San Diego, California, was founded in 1996, sold to Radiometer in 2000, and repurchased by company management and investors in 2003.

Complete Genomics' high quality, affordable DNA sequencing enables commercial-scale research of the genetic mechanisms underlying drug responses and complex diseases. Complete Genomics combines innovative technology with a disruptive market approach that will revolutionize DNA sequencing.

Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical identification and treatment of evaporative dry eye. Of the 100 million plus of dry eye sufferers worldwide, the leading cause (86percent) is evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye.

White Pine Medical, Inc. is a private equity firm specializing in late stage investing. The firm seeks to invest in medical device companies. The company was founded in 2010 and is based in Park City, Utah.

ikaSystems Corporation provides Web-based enterprise resource planning technology for process automation and intelligence management to support health insurers' commercial, and Medicare and Medicaid businesses. The company offers member portal, which supports administrative self-service; provider portal that automates processes, such as eligibility verification, claims submission, and authorization and referral submission and approval; employer portal, which includes online census/claims submissions, roster management, off-cycle transactions, electronic billing/reconciliation, and employer reporting functions for administrators; and admin portal that enables health plan administrative staff to complete transactions and manage health plan processes. It also provides ikaClaims, a claims administration and customer service system that delivers auto-adjudication rates; ikaBilling, a configurable premium billing solution, which allows health plans to set their rules for late payments and benefit revocation, and members and others to make payments online; ikaDWH, a database for claims, laboratory, pharmacy, encounter data, practice management, and electronic medical record information that supports standard and ad hoc report generation; and ikaCM and ikaDM, solutions that connect disease and case managers, physicians, and patients for information sharing and collaboration, as well as provides identification, stratification, enrollment, monitoring, alerting, and self-management tools. In addition, the company offers ikaProHEDIS+, a Web-based application that combines analytic and workflow tools to enable quality management; and ikaP4P, an real-time pay-for-performance application that allows health plans to define their P4P programs, set up P4P parameters, and monitprograms. It serves companies in the commercial, government, telecommunications, insurance, and financial sectors. The company was founded in 1999 and is headquartered in Southborough, Massachusetts.

Velcera is a specialty pharmaceutical company with a passion for assuring pets receive the medicines they need to support excellent overall health. At Velcera, they are dedicated to developing innovative, high-quality products for the pet health market. They comply with the highest standards of practice through all phases, from development to manufacturing to marketing.

Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems.

Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics.

Entellus Medical is focused on providing unique solutions to the unmet needs of the ENT (ear, nose and throat) physician, their patients, and payers through the development of innovative device technology and treatment solutions. Entellus is based in Maple Grove, MN and markets products throughout the United States. Entellus Medical works closely with leading researchers and clinicians to develop solutions that benefit patients, physicians, and payers. Entellus provides a simple, direct and effective treatment for Chronic Rhinosinusitis (CRS) that is less invasive, reduces pain and bleeding, shortens recovery time, and eliminates the need for general anesthesia. Entellus recently introduced FinESSâ„¢ Sinus Treatment, a simple and direct approach to effectively treat patients with CRS. FinESS can be performed under local anesthesia, with or without light sedation, and remodels the maxillary ostium and the ethmoid infundibulum using a micro endoscope and a small balloon catheter. Unlike sinus surgery techniques, FinESS does not require the removal of delicate bone or sinus tissue, resulting in shorter treatment time with very little pain or bleeding. Recovery time is usually one to two days with many patients resuming normal activity within a day.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

QSpex Technologies, Inc. has developed a unique and patented method to produce high quality premium lenses right in your office. It’s simple, cost effective and, above all, the lenses and treatment options provide the high quality you demand for your patients. All lens treatments are pre-applied to the inside surface of each mold and transfer to become part of the lens during the polymerization (curing) process.

Accumetrics is a privately-held company that develops, manufactures, and markets the VerifyNow System, a comprehensive suite of assays for the assessment of platelet function. Accumetrics, based in San Diego, California, was founded in 1996, sold to Radiometer in 2000, and repurchased by company management and investors in 2003.

Complete Genomics' high quality, affordable DNA sequencing enables commercial-scale research of the genetic mechanisms underlying drug responses and complex diseases. Complete Genomics combines innovative technology with a disruptive market approach that will revolutionize DNA sequencing.

Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye.

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders.

Victory Pharma, Inc. is a specialty pharmaceutical company that acquires, markets and develops prescription pharmaceutical products that treat pain and related conditions. Victory markets these products to health care professionals through an experienced US commercial organization. They also develop novel products that effectively treat pain and minimize side effects commonly associated with widely-used pain therapeutics.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.

Catalyst Biosciences is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and coagulation systems. They create novel catalytic biopharmaceutical products based on engineered human proteases.

ROX Medical is an early phase medical device company that is pioneering an innovative treatment for Chronic Obstructive Pulmonary Disease (COPD). Their therapy is intended to improve the delivery of oxygen to tissue to treat hypoxemia in COPD patients via the creation of a therapeutic fistula.

Nellix has developed an original device designed to address and expand the indication for the less invasive treatment of Abdominal Aortic Aneurysms (AAAs) and Thoratic Aortic Aneurysms (TAAs). Enabling the treatment of all aneurysms with a low profiles delivery system and innovative endograft, the Nellix device has the potential to double the market size for Endovascular Aneurysms Repair (EVAR), which exceeded $800M in 2008 with a 16% CAGR (Med Tech Insight).

Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye.

ATS Medical, doing business as Medtronic ATS Medical, Inc., is a medical device manufacturer that specializes in products for cardiovascular surgery. Mechanical heart valves, aortic valve graft prostheses, and other cardiovascular accessories are available from the company. Medtronic ATS Medical markets and distributes its products to the healthcare industry worldwide. ATS Medical was acquired by Medtronic on August 12, 2010

Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems.

Corium International is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development.

Orthovita is a spine and orthopedic biosurgery company that manufactures and markets orthobiologic and biosurgery products. Its orthobiologics platform offers products for the fusion, regeneration, and fixation of human bones; and the biosurgery platform provides products for controlling intra-operative bleeding. Orthovita sells its products directly, as well as through non-stocking distributors and independent sales agents in the United States; and directly and through independent stocking distributors internationally. The company has strategic partnerships with Kensey Nash Corporation, Angiotech Pharmaceuticals, and Medafor. It was founded in 1992 and is based in Malvern, Pennsylvania.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.

Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye.

Millennium Pharmacy Systems is a pharmacy services provider to the long-term care industry. Offering a new approach to pharmacy services, Millennium delivers on the promise of "the right drug, for the right patient, at the right time, for the right price" so its customers can deliver the best patient care while reducing costs, and more easily meeting compliance demands. Only Millennium combines Just-In-Time Dispensing with electronic medication and treatment ordering, administration, documentation, and reporting. Millennium backs up the commitment with delivery timeliness and medication accuracy customer guarantees. Millennium is headquartered in Chicago, Illinois.

StrataGent Life Sciences, Inc. is a specialty drug therapy company developing painless, non-invasive versions of therapies that would otherwise be injected. Its products are based on its proprietary microjet technology, which delivers large and small therapeutic molecules without a device penetrating into or through the skin. In May of 2004, StrataGent received a $2 million award from the Advanced Technology Program (ATP) at the National Institute of Standards and Technology to support the development of the StrataGent microjet technology.

Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Alaunos Therapeutics is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.

Ception Therapeutics is a biopharmaceutical company focused on the discovery and development of novel products to address areas of unmet medical need. Ception was founded by experienced pharmaceutical executives in order to develop and commercialize therapeutics in areas of significant unmet medical need.

Healthcare Brands International (HBI) is a new company helping to turn innovative medical product technology into successful consumer brands.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Prism Pharmaceuticals, Inc., an acute care pharmaceutical company, engages in developing and commercializing cardiovascular injectable products in the United States. Its products include NEXTERONE, an anti arrhythmic agent in the form of injectable amiodarone; and PM103, an intravenous formulation of clopidogrel bisulfate. The company was founded in 2004 and is based in King of Prussia, Pennsylvania.

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.

Touchstone Health, a New York-based Medicare Advantage insurer. Touchstone offers a diverse portfolio of Medicare Advantage product options, including a choice of zero and low dollar co-pay plans with benefits including medical, pharmacy dental and mental health.

Breg is a sports medicine company that specializes in bracing and cold therapy. They provide remarkably easy products, services, technology, and consulting to improve orthopedic episodes, from conservative treatment to pre-surgery and post-surgery.

Light Sciences Oncology develops cancer and tumor treatment drugs. Additionally, it offers oncology drugs research and development services to treat hepatocellular carcinoma, metastatic colorectal cancer, and glioma. Light Sciences Oncology was founded in 1994 and is headquartered in Bellevue, Washington.

Receptor Biologix develops receptor-based biological therapeutics for cancer, inflammatory, and autoimmune diseases. The company is headquartered in Palo Alto, California.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international (55% of revenue), Salix pharmaceuticals (25%), ortho dermatology (6%), and diversified products (14%), and approximately 13% of revenue is attributable to non-U.S. markets. Bausch is the market leader in consumer visioncare in India and China, and the fourth- largest visioncare company by sales in the United States.

Dow Pharmaceutical Sciences, Inc. engages in the development of topical drug products for pharmaceutical and biotechnology clients.

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.

MediciNova is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers

LipoSonix, Inc. operates as a medical device company. The company develops non-invasive body sculpting products for aesthetic applications. The company was founded in 1999 and is based in Bothell, Washington. As of July 1, 2008, LipoSonix, Inc. operates as a subsidiary of Medicis Pharmaceutical Corp.

Accumetrics is a privately-held company that develops, manufactures, and markets the VerifyNow System, a comprehensive suite of assays for the assessment of platelet function. Accumetrics, based in San Diego, California, was founded in 1996, sold to Radiometer in 2000, and repurchased by company management and investors in 2003.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

Inhibitex develops antibody based products to prevent and treat bacterial and fungal infections. The company is focused on the development of small molecule antiviral compounds, and in particular, therapies to treat shingles and chronic hepatitis C infections.

BioForm Medical, Inc., a medical aesthetics company, focuses on developing and commercializing products that are used by physicians to enhance a patient's appearance. Its core product is RADIESSE, an injectable dermal filler used to provide aesthetic improvement for patients. It markets its products through sales representatives and third party distributors to dermatologists, plastic surgeons, facial plastic surgeons, and other physicians performing cosmetic procedures in the United States, Europe, and internationally.

Rinat, which means "happiness" in Hebrew, was formed in 2001 when Genentech, a leader in the development of therapeutic antibodies, narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. Genentech invested significant R&D resources in support of these assets over 15 years, and Rinat is now building on them as the pioneer in developing and commercializing antibody drugs for the treatment of diseases and disorders of the nervous system.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.